StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Friday morning. The firm issued a sell rating on the stock.

A number of other analysts have also recently commented on OCX. Needham & Company LLC lowered their price target on OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a research note on Thursday, August 10th. Benchmark lowered their price target on OncoCyte from $9.00 to $5.00 and set a speculative buy rating for the company in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $7.31.

OncoCyte Stock Performance

OncoCyte stock opened at $3.37 on Friday. OncoCyte has a 1 year low of $3.18 and a 1 year high of $18.20. The company’s 50-day moving average is $3.60 and its two-hundred day moving average is $4.06.

OncoCyte (NASDAQ:OCX) last released its earnings results on Thursday, August 10th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.60) by $1.53. The business had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. As a group, equities analysts expect that OncoCyte will post -3.03 earnings per share for the current year.

Institutional Trading of OncoCyte

Large investors have recently bought and sold shares of the business. Raymond James Financial Services Advisors Inc. bought a new position in shares of OncoCyte during the 1st quarter worth approximately $25,000. Vanguard Group Inc. boosted its holdings in shares of OncoCyte by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,986,270 shares of the company’s stock valued at $5,940,000 after buying an additional 90,534 shares during the last quarter. DCF Advisers LLC boosted its holdings in shares of OncoCyte by 107.0% in the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after buying an additional 13,000 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in OncoCyte by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 460,004 shares of the company’s stock valued at $686,000 after purchasing an additional 24,964 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in OncoCyte by 58.1% during the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after purchasing an additional 40,000 shares during the last quarter.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.